Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

Yumeng Zhang, MD, Hannah H Asghari, MD, Onyee Chan, MD, Dasom Lee, MD, Martine Extermann, MD, Najla Al Ali, M.Sc, Yehuda E. Deutsch, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, David A Sallman, MD, Chetasi Talati, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 1368.

https://doi.org/10.1182/blood-2019-127772

Published: 2019

Journal Articles

Hypomethylating Agents Versus Intensive Chemotherapy in Elderly Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Eric Padron, MD, Alan F. List, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 3911.

https://doi.org/10.1182/blood.V130.Suppl_1.3911.3911

Published: 2017

Journal Articles

Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Alan F List, MD, Eric Padron, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 3912.

https://doi.org/10.1182/blood.V130.Suppl_1.3912.3912

Published: 2017

Journal Articles

Effect of NPM1 Mutation on Prognosis and Therapeutic Efficacy in Patients Aged ≥70 Years with Acute Myeloid Leukemia

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Alan F. List, MD, Eric Padron, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 2676.

https://doi.org/10.1182/blood.V130.Suppl_1.2676.2676

Published: 2017

Journal Articles

Defining Acute Myeloid Leukemia Ontogeny in Older Patients

Megan Melody, BA, MS, David A Sallman, MD, Najla Al Ali, M.Sc, Hanadi Ramadan, BA, Ling Zhang, MD, Eric Padron, MD, Kendra Sweet, MD, Martine Extermann, MD, Alan F List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2017) 130 (Supplement 1): 2594.

https://doi.org/10.1182/blood.V130.Suppl_1.2594.2594

Published: 2017

Journal Articles

Outcomes in Older Adults (age ≥ 70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype

Blood (2017) 130 (Supplement 1): 1412.

https://doi.org/10.1182/blood.V130.Suppl_1.1412.1412

Published: 2017

Journal Articles

Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age ≥70) Is Karyotype Dependent

Blood (2017) 130 (Supplement 1): 1413.

https://doi.org/10.1182/blood.V130.Suppl_1.1413.1413

Published: 2017

Journal Articles

Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients

Martine Extermann, MD PhD, Marina Sehovic, MD MPH, Tea Reljic, MPH, Jongphil Kim, PhD, Jeffrey E. Lancet, MD, Benjamin Djulbegovic, MD PhD

Blood (2016) 128 (22): 3998.

https://doi.org/10.1182/blood.V128.22.3998.3998

Published: 2016

Journal Articles

When Should Patients Older Than 70 with Acute Myeloid Leukemia be Treated?

Jongphil Kim, Martine Extermann, MD PhD, Jeffrey E. Lancet, MD, Najla H Al Ali, Tea Reljic, MPH, Marina Sehovic, MD MPH, Varun C Dhulipala, MD, Benjamin Djulbegovic, MD PhD

Blood (2016) 128 (22): 4007.

https://doi.org/10.1182/blood.V128.22.4007.4007

Published: 2016

Journal Articles

Body Composition Predicts Survival in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients

Asmita Mishra, MD, Binglin Yue, Martine Extermann, MD PhD, Claudio Anasetti, MD, Heather Jim, Jongphil Kim, Joseph A Pidala, MD, PhD, Vickie E Baracos

Blood (2015) 126 (23): 2113.

https://doi.org/10.1182/blood.V126.23.2113.2113

Published: 2015

Journal Articles

Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of over 600 Patients

Varun C Dhulipala, MD, Martine Extermann, MD PhD, Najla Al Ali, Jongphil Kim, Marina Sehovic, MD MPH, Tea Reljic, Benjamin Djulbegovic, MD PhD, Jeffrey E Lancet, MD

Blood (2015) 126 (23): 2505.

https://doi.org/10.1182/blood.V126.23.2505.2505

Published: 2015

Journal Articles

Treatment of Diffuse Large B-Cell Lymphoma and Preexisting Congestive Heart Failure: A Retrospective Analysis from Moffitt Cancer Center TCC Database

Vérène Dougoud-Chauvin, MD, Michael G Fradley, MD, Lu Chen, Jongphil Kim, Christine M Walko, PharmD,BCOP, Marina Sehovic, Martine Extermann, MD PhD

Blood (2015) 126 (23): 3957.

https://doi.org/10.1182/blood.V126.23.3957.3957

Published: 2015

Journal Articles

Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience

Heather Barnes Pound, PharmD, BCPS, Viet Q. Ho, PharmD, BCOP, Celeste M. Bello, MD, Jennifer L. Cultrera, MD, Martine Extermann, MD, PhD, Jeffrey E. Lancet, MD, Eduardo M. Sotomayor, Javier Pinilla-Ibarz, MD, PhD

Blood (2011) 118 (21): 4620.

https://doi.org/10.1182/blood.V118.21.4620.4620

Published: 2011

NARROW

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

Hypomethylating Agents Versus Intensive Chemotherapy in Elderly Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count

Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality

Effect of NPM1 Mutation on Prognosis and Therapeutic Efficacy in Patients Aged ≥70 Years with Acute Myeloid Leukemia

Defining Acute Myeloid Leukemia Ontogeny in Older Patients

Outcomes in Older Adults (age ≥ 70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype

Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age ≥70) Is Karyotype Dependent

Type of Therapy May Influence Outcomes in Patients over Age 70 with Acute Myeloid Leukemia: A Systematic Review of More Than 11,000 Patients

When Should Patients Older Than 70 with Acute Myeloid Leukemia be Treated?

Body Composition Predicts Survival in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients

Survival Comparison Amongst Commonly Used Frontline Regimens in Patients Age 70 Years and Older with Acute Myeloid Leukemia (AML): A Single-Institution Study of over 600 Patients

Treatment of Diffuse Large B-Cell Lymphoma and Preexisting Congestive Heart Failure: A Retrospective Analysis from Moffitt Cancer Center TCC Database

Bendamustine and Rituximab for the Treatment of Chronic Lymphocytic Leukemia: The Moffitt Cancer Center Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only